FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular, pertains to antibodies to CD11b or to the antigen-binding part of said antibodies, as well as to effective methods and a use of the antibodies for modulation of the immune response by means of regulation of CD11b expression in cells.
EFFECT: invention provides a possibility of effectively regulating the expression of CD11b in cells.
11 cl, 20 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR OBTAINING UP-REGULATING PD-L1 EXPRESSION, POLYPEPTIDES, A CONJUGATE, A FUSED POLYPEPTIDE, A COMPOSITION AND A COMBINATION TO PROVIDE UP-REGULATING EXPRESSION OF PD-L1 | 2016 |
|
RU2734169C2 |
| ANTIBODY AGAINST PROGRAMMED CELL DEATH PROTEIN 1 (PD-1) AND APPLICATION THEREOF | 2015 |
|
RU2661678C1 |
| ANTIBODIES AGAINST THE PROGRAMMED DEATH LIGAND (PD-L1) AND APPLICATION THEREOF | 2019 |
|
RU2761638C1 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2014 |
|
RU2663795C2 |
